Sarepta Gene Therapy Scrutiny - Search News

Order byBest matchMost fresh

News

Sarepta Shares Fall

· 1d · on MSN

Sarepta fails to win EU backing for muscle disorder gene therapy

Sarepta Therapeutics failed to win the European drug regulator's backing for its muscle disorder gene therapy on Friday, as the company faces intense regulatory scrutiny after two recent patient deaths tied to the treatment.

Continue reading

· 1d · on MSN

What’s behind Sarepta’s gene therapy deaths?

· 2d · on MSN

Sarepta Shares Fall After EU Regulator Rejects Gene Therapy

Europe moves to reject embattled Duchenne muscular dystrophy gene therapy

European regulators said that a Duchenne gene therapy should not be approved, imperiling the treatment that is also facing ...

Fierce Biotech9d

UPDATED: Analysts demand transparency after Sarepta's roundabout disclosure of 3rd patient death

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Sarepta Therapeutics Announces Layoff of 493 Employees, Including 80 in Ohio, Amid FDA Scrutiny and Stock Decline

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results